Delivery Order SPE2DB22D1202-SPE2DB25FVGW4
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,553.06 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count) with an ultimate completion date of December 9, 2025. This is a firm fixed price delivery order with no set-aside designation, reflecting competitive award criteria. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This...
- The Defense Logistics Agency awarded a delivery order valued at $2,528.49 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in a 30-count package. The contract is a firm fixed price delivery order with an ultimate completion date of November 10, 2025, and was competitively awarded with no set-aside designation. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $6,642.00 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This competitive award, issued on August 28, 2025, with an ultimate completion date of August 29, 2025, represents a firm fixed-price transaction with no set-aside designation. The pharmaceutical will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $5,660.39 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 MG tablets (30-count packages) with a firm fixed price structure. The contract, awarded July 31, 2025, represents a non-set-aside, competitively awarded delivery order with an ultimate completion date of August 1, 2025. Performance will be executed from the vendor's location in Conshohocken, Pennsylvania, the company's corporate headquarters. This...
- The Defense Logistics Agency awarded a delivery order valued at $8,939.49 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 MG tablets (30-count packages) on July 29, 2025, with completion scheduled for July 30, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of the company's role as a...
- The Defense Logistics Agency awarded a delivery order valued at $18,470.50 to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count packaging). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 28, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a routine...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,407.70 for the supply of Ondansetron ODT 4 mg tablets (30-count) on December 9, 2025, with ultimate completion by December 10, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of the company's extensive...
- The Defense Logistics Agency awarded a $4,445.95 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT (orally disintegrating tablet) 4 mg tablets in quantities of 30, with an ultimate completion date of June 20, 2025. This competitively awarded, firm fixed-price contract reflects a non-set-aside procurement and represents a continuation of AmerisourceBergen's ongoing pharmaceutical supply relationship with DLA. The contract specifies performance at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $5,996.73 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order was executed on August 14, 2025, with an ultimate completion date of August 15, 2025. The contract does not include a set-aside designation. Performance will be fulfilled from AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,413.45 for Ondansetron ODT 4 mg tablets (30-count supply) on August 1, 2025, with a completion date of August 4, 2025. This non-competitive, firm fixed price delivery order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a continuation of the company's extensive pharmaceutical supply relationship with DLA, supporting federal medical procurement...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVGW4Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,706.96 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). The contract is firm fixed price with no set-aside designation and is scheduled for completion by August 11, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania will serve as the place of performance for this pharmaceutical delivery. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999,999,999.00 prime vendor agreement extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs worldwide. Through competitive procurement, AmerisourceBergen has established itself as a critical vendor within the Defense Health Agency and federal medical supply chain, with demonstrated capability to fulfill diverse pharmaceutical requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.7k | 8/8/25 |